Concordances and predictors of biopsies in renal tumors.
CONCLUSION: In renal tumor care, renal biopsy is a reliable testing. However, some factors most likely linked to the tumor anatomy (intra-sinusal tumor) and their histological composition were involved in the lack of non-contribution to the diagnosis. LEVEL OF EVIDENCE: 4. PMID: 31629660 [PubMed - as supplied by publisher]
Publication date: Available online 20 November 2019Source: Urology Case ReportsAuthor(s): Eric M. Chevli, Tyler J. Maiers, David J. Abramowitz, Shervin Badkhshan, John J. BodkinAbstract:Situs inversus totalis (SIT) is a rare condition with left-right mirror imaging of both abdominal and thoracic organs. While this configuration is rarely of medical importance, an understanding of this unique anatomy is essential in the setting of surgical intervention. Here we review a case of renal cell carcinoma (RCC) in the setting of SIT. The patient underwent a hand-assisted laparoscopic radical nephrectomy. Pathology revealed pT3aNxM...
Condition: Clear Cell Renal Cell Carcinoma Intervention: Drug: ARO-HIF2 Sponsor: Arrowhead Pharmaceuticals Not yet recruiting
Authors: Zhao L, Liu K, Pan X, Quan J, Zhou L, Li Z, Lin C, Xu J, Xu W, Guan X, Li H, Ni L, Gui Y, Lai Y Abstract Clear cell renal cell carcinoma (ccRCC) is a common malignancy, yet, the mechanisms underlying tumorigenesis remain unclear. Several miRNAs have been implicated in the development of RCC previously via regulation of target gene expression. As miR-625-3p has recently been identified to play a role in development of other malignancies and is reportedly upregulated in ccRCC, we sought to investigate the role of this miRNA in the progression of ccRCC. Analysis of 30 paired fresh ccRCC tissues and adjacent n...
Nivolumab is a fully human, immunoglobulin G4 (kappa) isotype monoclonal antibody that binds programmed cell death protein 1 (PD-1) on activated immune cells and disrupts the engagement of the receptor with its ligands programmed death-ligand 1 (PD-L1: B7-H1/CD274 and PD-L2: B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the antitumor response of the host . In previous clinical trials, nivolumab has shown activity in several tumor types, including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), hodgkin lymphoma, and malignant pleural mesothelioma.
Conclusion: CK7, CD117, and Claudin-7 are frequently expressed in CHRCC with high specificity. We recommend the routine use of these 3 markers as a routine panel when making a differential diagnosis of CHRCC and excluding other mimics. PMID: 31737127 [PubMed - in process]
ConclusionsThe evidence from this study and previous work highlights the importance of the assumptions underlying any model structure, and the need to validate assumptions regarding survival and the application of treatment effects against what is known about the characteristics of the disease.
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 38-year-old woman is evaluated during a follow-up visit for primary membranous glomerulopathy. Diagnosis was made by kidney biopsy 4 months ago, and she was found to be positive for anti–phospholipase A2 receptor (PLA2R) antibodies. Medications are furosemide, losartan, and simvastatin. […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): A. Kawashima, M. Matsumoto, Y. Kidani, T. Yoshida, M. Matsushita, Y. Koh, K. Nakano, Y. Hayashi, Y. Ishizuya, C. Wang, T. Kato, T. Ujike, K. Fujita, M. Uemura, S. Sakaguchi, M. Nagira, N. Ohkura, H. Wada, N. Nonomura
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): G. Procopio, G. Apollonio, F. Cognetti, R. Miceli, M. Milella, A. Mosca, V.E. Chiuri, A. Bearz, F. Morelli, C. Ortega, F. Atzori, M. Donini, R. Ratta, A. Raimondi, M. Claps, A. Martinetti, U. Capitanio, F.G. De Braud, V. Cappelletti, E. Verzoni
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): L. Polanco Pujol, F. Herranz Amo, J. Caño Velasco, J. Mayor De Castro, J. Aragon Chamizo, C. Hernandez Fernandez